Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops… Read more
Erasca Inc (ERAS) - Total Liabilities
Latest total liabilities as of September 2025: $72.52 Million USD
Based on the latest financial reports, Erasca Inc (ERAS) has total liabilities worth $72.52 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Erasca Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Erasca Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Erasca Inc Competitors by Total Liabilities
The table below lists competitors of Erasca Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inner Mongolia Junzheng Energy & Chemical Group Co Ltd
SHG:601216
|
China | CN¥12.82 Billion |
|
Loomis AB (publ)
PINK:LOIMF
|
USA | $26.51 Billion |
|
Solaris Energy Infrastructure, Inc.
NYSE:SEI
|
USA | $708.09 Million |
|
International Seaways Inc
NYSE:INSW
|
USA | $648.37 Million |
|
BRP Inc
NASDAQ:DOOO
|
USA | $5.93 Billion |
|
Fastly, Inc. Class A Common Stock
NYSE:FSLY
|
USA | $569.90 Million |
|
Wuhan Jingce Electronic Technology Co Ltd
SHE:300567
|
China | CN¥5.70 Billion |
|
Black Stone Minerals LP
NYSE:BSM
|
USA | $207.10 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Erasca Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Erasca Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Erasca Inc (2019–2024)
The table below shows the annual total liabilities of Erasca Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $79.03 Million | +0.53% |
| 2023-12-31 | $78.61 Million | -23.72% |
| 2022-12-31 | $103.06 Million | +129.59% |
| 2021-12-31 | $44.89 Million | -81.20% |
| 2020-12-31 | $238.81 Million | +245.52% |
| 2019-12-31 | $69.12 Million | -- |